Use-results survey of Matsudaito

Prospective registry study of efficacy and safety on post marketing surveillance of Matsudaito for hemostasis of vascular anastomosis - Prospective registry study on post marketing surveillance of Hydrofit

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000047562

Enrollment

500

Registered

2022-04-22

Start date

2014-06-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracic aorta aneurism or dissection

Interventions

Hemostasis with Hydrofit

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Patients treated with Hydrofit to stop bleeding 2 Patient registered on use-result survey of Hydrofit

Exclusion criteria

Exclusion criteria: not determined

Design outcomes

Primary

Measure	Time frame
Incidence of defects and adverse events during 1 year follow-up	—

Secondary

Measure	Time frame
Hemostatic effect during surgical procedure, and presence/absence of additional hemostatic procedures	—

Countries

Japan

Contacts

Public ContactHiroaki Maeda

Sanyo Chemical Industries, Ltd. Biotechnology & Medical Division Regulatory Affairs dept.

h.maeda@sanyo-chemical.group075-541-6310

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026